* Conmed Corp CNMD.N CNMD.K is expected to show a rise
in
quarterly revenue when it reports results on July 26.
* The Largo Florida-based company is expected to report a
10.4% increase in revenue to $306.09 million from $277.19
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. The company's guidance on
April 26 2023, for the period ended June 30, was for revenue
between $300.00 million and $310.00 million.
* Refinitiv's mean analyst estimate for Conmed Corp is for
earnings of 79 cents per share. The company's EPS guidance on
April 26 2023, for the period ended June 30, was between $0.77
and $0.82
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Conmed Corp
is
$129, above its last closing price of $121.60.
The company's guidance on April 26 2023 for the period ended
June 30 was for gross profit margin between USD54% and USD56%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.60 0.60 0.66 Beat 10.3
Dec. 31 2023 0.89 0.90 0.42 Missed -53.5
Sep. 30 2022 0.75 0.75 0.77 Beat 2.4
Jun. 30 2022 0.74 0.75 0.76 Beat 1.8
Mar. 0.62 0.62 0.70 Beat 13.3
31 2022
Dec. 31 2021 1.03 1.03 1.07 Beat 4
Sep. 30 2021 0.75 0.75 0.80 Beat 6.7
Jun. 30 2021 0.62 0.62 0.71 Beat 14.5
This summary was machine generated July 25 at 02:04 GMT. All
figures in US dollars unless otherwise stated